CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer. by Komdeur, F, Prins, T, van de Wall, S, Plat, A, Wisman, G, Hollema, H, Daemen, T, Church, D, de Bruyn, M, Nijman, H

Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibitio... by Eggink, F, Van Gool, I, Leary, A, Pollock, P, Crosbie, E, Mileshkin, L, Jordanova, E, Adam, J, Freeman-Mills, L, Church, D, Creutzberg, C, De Bruyn, M, Nijman, H, Bosse, T

POLE proofreading mutations elicit an anti-tumor immune response in endometrial cancer by Klenerman, P, Church, D, Tomlinson, I, van Gool, I, Eggink, F, Freeman-Mills, L, Stelloo, E, Marchi, E, de Bruyn, M, Palles, C, Nout, R, de Kroon, C, Osse, E, Creutzberg, C, Smit, V, Nijman, H, Bosse, T

A transcriptionally distinct CXCL13+ CD103+ CD8+ T-cell population is associated with B-cell 2 recruitment and neoantigen load in human cancer by Workel, H, Lubbers, J, Arnold, R, Prins, T, Van Der Vlies, P, De Lange, K, Bosse, T, Van Gool, I, Eggink, F, Wouters, M, Komdeur, F, Creutzberg, C, Kol, A, Plat, A, Glaire, M, Church, D, Nijman, H, De Bruyn, M